Eledon Pharmaceuticals (FRA:2TK) Long-Term Capital Lease Obligation : €0.51 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Long-Term Capital Lease Obligation?

Eledon Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €0.51 Mil.

Eledon Pharmaceuticals's quarterly Long-Term Capital Lease Obligation increased from Sep. 2024 (€0.28 Mil) to Dec. 2024 (€0.61 Mil) but then declined from Dec. 2024 (€0.61 Mil) to Mar. 2025 (€0.51 Mil).

Eledon Pharmaceuticals's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (€0.36 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.61 Mil).

Eledon Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Eledon Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Long-Term Capital Lease Obligation Chart

Eledon Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.35

0.36

0.61

Eledon Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	0.36	0.28	0.61	0.51

Eledon Pharmaceuticals (FRA:2TK) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Eledon Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Eledon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ELDN:USA

Address

19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612

Website

https://www.eledon.com

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals Headlines

No Headlines